Data abstracted from studies with active follow-up of chlamydial and gonococcal reinfection among men
| Author, year(reference) | Population | n | Follow-up method | Follow-up period | % of enrolled men with follow-up (n) | % of men with repeat chlamydia (n) | % of men with repeat gonorrhea (n) | % of men with repeat gonorrhoea/chlamydia (n) | % of female data (n) |
|---|---|---|---|---|---|---|---|---|---|
| F, female; M, male; NA, not applicable; STD, sexually transmitted disease. | |||||||||
| *Follow-up period was for 1 year, but abstracted data are limited to first follow-up at 3 months. | |||||||||
| †Repeat chlamydia/gonorrohea defined as either chlamydial or gonococcal infection in men coinfected with chlamydia and gonorrhoea at baseline. | |||||||||
| ‡Follow-up is defined as participants with at least one follow-up visit. If 1-month visit was not available, 4-month visit was used. | |||||||||
| §Repeat chlamydia/gonorrohea defined as chlamydial infection at follow-up in men with chlamydia at baseline or gonococcal infection at follow-up in men with gonorrhoea at baseline. | |||||||||
| ¶Measure is overall follow-up rate. Male-specific data were not available. | |||||||||
| **Defined as at least one mailed specimen collected 2–24 weeks after baseline mailed specimen. | |||||||||
| ††Reported reinfection data are defined as a new infection between 2 and 12 weeks after initial infection. | |||||||||
| ‡‡Repeat chlamydia/gonorrohea defined as chlamydia infection at follow-up in men with chlamydia at baseline or gonococcal infection at follow-up in men with gonorrhoea at baseline or either infection in men coinfected with chlamydia and gonorrhoea at baseline. | |||||||||
| Peterman et al,200645 | STD, clinic-based; Newark, Denver and Long Beach: chlamydia and/or gonorrhoea-infected subset of 2419 clinics, patients aged 15–39 years, enrolled in HIV prevention counselling study | 246 M, 133 F | Scheduled 3 month follow-up visit at respective STD clinic | 3 months* | 83.3 (205/246) | 9.8 (112) | 14.9 (68) | 20.0† (25) | CHLAMYDIA: 10.7 (84) GONORRHOEA: 3.6 (30) |
| Bernstein et al,200646 | STD, clinic-based; Baltimore, Maryland: people diagnosed as having gonorrhoea at public STD clinic | 548 M, 119 F | Scheduled follow-up visit or follow-up by disease investigation specialists | 3 months | 24.3 (133/548) | NA | 30.8 (41/133) | NA | GONORRHOEA: 28.9 (13/45) |
| Ellen et al,200647 | Various venues; Baltimore and Denver: asymptomatic chlamydia and/or gonorrhoea infected males aged 13–25 years | 314 M | Scheduled follow-up visits at 1 and 4 months | 4 months | 44.3‡ (139/314) | NA | NA | 6.5§ (9/139) | NA |
| Golden et al,200543 | Population based; King County, Washington: partner-notified heterosexuals who returned mailed rescreening kits | 57 M, 124 F | Mailed retesting kit 3 months after treatment | 3 months | 35.8¶ (221/618) | 10.7 (6/56) | 0.0 (0/14) | NA | CHLAMYDIA: 7.6 (11/144) GONORRHOEA: 16.7 (2/12) |
| Golden et al,200529 | Population based; King County, Washington: gonorrhoea and/or chlamydia-infected women and heterosexual men with untreated partners | 646 M, 2105 F | Reinterview and retest | 19 weeks | 61.3 (396/646) | 10.1 (27/267) | 7.0 (11/157) | 9.1‡ (37/396) | CHLAMYDIA: 12.3 GONORROHEA: 7.0 CHLAMYDIA/GONORROHEA: 12.0 |
| Sparks et al,200448 | STD, clinic based; King County, Washington: asymptomatic chlamydia and/or gonorrhoea infected heterosexual males and females aged ⩾14 years | 84 M, 38 F | Mailed or clinic retesting 10–24 weeks after treatment | 24 weeks | 63.4 (71/112) | 16.0 (6/38) | 0.0 (0/9) | NA | CHLAMYDIA: 0 (0/20) GONORRHOEA: 25 (1/4) |
| Dunne et al,200444 | Various venues; Baltimore, Denver and San Francisco: chlamydia-infected men | 361 M | Scheduled follow-up visits at 1 and 4 months | 4 months | 76.0 (272/358) | 11.4 (31/272) | NA | NA | NA |
| Kjaer et al,200049 | Population based; Ringkjobing, Denmark: chlamydia-infected general practice patients aged ⩾18 years who had not been treated with antibiotics in previous 4 weeks | 12 M, 30 F | Serial mailed specimens collected at 2, 4, 8, 12 and 24 weeks | 24 weeks | 83.3** (10/12) | 11.1†† (1/9) | NA | NA | 12.0‡‡ (3/25) |